- Home
- NEXN vs RLMD Comparison
NEXN vs RLMD Comparison
Compare NEXN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXN | RLMD |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | Israel | United States |
| Employees | 909 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 381.1M | 319.7M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | NEXN | RLMD |
|---|---|---|
| Price | $7.03 | $7.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $11.56 | ★ $12.40 |
| AVG Volume (30 Days) | 252.5K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $5.60 | $0.27 |
| 52 Week High | $12.00 | $7.94 |
Technical Indicators
Market Signals| Indicator | NEXN | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 61.58 |
| Support Level | $6.23 | $3.49 |
| Resistance Level | $7.71 | $7.41 |
| Average True Range (ATR) | 0.31 | 0.44 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 81.86 | 59.43 |
Price Performance
Historical ComparisonAbout NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and TV that helps empower advertisers, agencies, digital publishers, broadcasters, and others. The Digital Advertising Ecosystem of the company includes demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. The company operates in America, APAC, EMEA, and Rest of America, with majority revenue from America.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.